Chemotherapy Administration

Philip Haywood, Johan Raad, Kees Gool, Marion Haas, Gisselle Gallego, Sallie-Anne Pearson, Margaret Faedo and Robyn Ward
Additional contact information
Johan Raad: Utrecht University
Kees Gool: University of Technology Sydney
Sallie-Anne Pearson: University of New South Wales, Prince of Wales Clinical School
Margaret Faedo: University of New South Wales, Prince of Wales Clinical School
Robyn Ward: University of New South Wales, Prince of Wales Clinical School

PharmacoEconomics, 2012, vol. 30, issue 12, No 7, 1173-1186

Abstract: Abstract Background and Objective The increasing cost of chemotherapy is placing greater pressures on limited healthcare budgets. A potentially important, but often overlooked, aspect of chemotherapy is the cost associated with administration. This study aims to develop a better understanding of these costs, and in doing so, develop a model to estimate the comparative cost of administering alternative chemotherapy protocols for economic evaluation or local decision making. Methods We identified the potential tasks and choices related to administering intravenous chemotherapy, grouped tasks according to anticipated resource use, and allocated costs to each task using data from an evidence-based collection of cancer protocols or from primary data collection. The resources were costed from a healthcare system perspective using standard data sources within Australia. The model was applied to alternative protocols used in the treatment of three different cancers: locally advanced and metastatic non-small-cell lung cancer, adjuvant colorectal cancer and adjuvant breast cancer. Results For the three cancer types examined, the cost of completed administration ranged from 1274 Australian dollars ($A) to $A3015 (year 2009 values) for 13 different protocols potentially used for the initial treatment of locally advanced and metastatic non-small-cell lung cancer; $A5175–8445 for seven protocols for adjuvant colorectal cancer treatment; and $A1494–4074 for seven protocols for adjuvant breast cancer treatment. Conclusions The results are of practical significance to those undertaking economic evaluations and to decision makers who use this information within the area of chemotherapy. The examples used suggest that administration costs per visit varied inversely with the number of visits. The results provide information where little has previously been available and may allow decisions about costs and resource allocation to be made with more certainty. Although our model uses costs from the public health system within an Australian state (New South Wales), it can be adapted for use in other jurisdictions.

Keywords: Docetaxel; Pemetrexed; Chemotherapy Protocol; Administration Cost; Peripherally Insert Central Catheter (search for similar items in EconPapers)
Date: 2012
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.2165/11597280-000000000-00000 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
Journal Article: Chemotherapy Administration (2012)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:30:y:2012:i:12:d:10.2165_11597280-000000000-00000

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.2165/11597280-000000000-00000

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().